IMM0306 is a bispecific antibody targeting CD20 on B cells and CD47 to block the CD47-SIRPα immune checkpoint. It enhances macrophage and NK cell-mediated phagocytosis and cytotoxicity, exhibiting potential immunostimulating, phagocytosis-inducing and antineoplastic activities, making it a promising immunotherapy for B-cell malignancies. M.W 174.12 kDa